WO2004017970A1 - Piperidin-2,6-dione pamoate salts and their use for the treatment of stress-related affective disorders - Google Patents

Piperidin-2,6-dione pamoate salts and their use for the treatment of stress-related affective disorders Download PDF

Info

Publication number
WO2004017970A1
WO2004017970A1 PCT/IB2003/003698 IB0303698W WO2004017970A1 WO 2004017970 A1 WO2004017970 A1 WO 2004017970A1 IB 0303698 W IB0303698 W IB 0303698W WO 2004017970 A1 WO2004017970 A1 WO 2004017970A1
Authority
WO
WIPO (PCT)
Prior art keywords
pamoate
dione
sleep
pamoate salt
stress
Prior art date
Application number
PCT/IB2003/003698
Other languages
French (fr)
Inventor
Camille Georges Wermuth
Original Assignee
Prestwick Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DE60306396T priority Critical patent/DE60306396T2/en
Priority to US10/524,693 priority patent/US7514454B2/en
Priority to JP2004530467A priority patent/JP2005538146A/en
Priority to CA002495377A priority patent/CA2495377A1/en
Priority to MXPA05001919A priority patent/MXPA05001919A/en
Priority to BR0313674-4A priority patent/BR0313674A/en
Priority to SI200330438T priority patent/SI1539160T1/en
Priority to NZ538341A priority patent/NZ538341A/en
Application filed by Prestwick Pharmaceuticals, Inc. filed Critical Prestwick Pharmaceuticals, Inc.
Priority to AU2003255947A priority patent/AU2003255947B2/en
Priority to EP03792588A priority patent/EP1539160B1/en
Priority to EA200500242A priority patent/EA007900B1/en
Priority to UAA200501443A priority patent/UA80144C2/en
Publication of WO2004017970A1 publication Critical patent/WO2004017970A1/en
Priority to IL166941A priority patent/IL166941A/en
Priority to NO20051471A priority patent/NO20051471L/en
Priority to CY20061101323T priority patent/CY1105541T1/en
Priority to US12/382,511 priority patent/US20090182012A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Definitions

  • the present invention relates to pamoate salts of certain 3-phenyl-3- dimethylaminoalkyl-4,4-dimethylpiperidin-2,6-diones and their use in the treatment of stress-related affective disorders.
  • stress-induced affective disorder is used herein to include any disorder associated with elevated levels of 5-HT (5- hydroxytryptamine; serotonin) resultant from newly synthesised 5-HT.
  • R T represents methoxy, ethoxy or hydroxy
  • R 2 represents methoxy, ethoxy, hydroxy or hydrogen; and n represents 2 or 3.
  • AGN 2979 (which designation will be used in this application); BTG 1501 ; MDL 72415 and SC 48274.
  • a large number of acid addition salts of AGN 2979 have been proposed but the hydrochloride has been the salt of choice because hydrochloride acid addition salts are the most commonly used acid addition salts and can be readily and inexpensively prepared and there was no reason to believe that any other salts would have any advantage over the hydrochloride.
  • pamoate salts instead of the hydrochloride, or other previously disclosed salt, of compounds of Formula I.
  • these pamoate salts do not cause weight loss and the indications are that they will not cause hepatocyte changes over prolonged periods of treatment.
  • the pamoate salts of the compounds of Formula I contrary to the known salts, are tasteless and allow the preparation of pharmaceutical compositions for the oral administration, especially in form of suspensions, syrups and the like.
  • Ri represents methoxy, ethoxy or hydroxy
  • R 2 represents methoxy, ethoxy, hydroxy or hydrogen
  • n represents 2 or 3, and pharmacologically acceptable solvates thereof.
  • Pamoic acid is 4,4'-methylenebis[3-hydroxy-2-naphthalenecarboxylic acid] and is also known as embonic acid.
  • the compounds of Formula I exist in optical isomers and accordingly the pamoate salts can be used in racemate form or as individual (+) or (-) isomers. Presently the (-) isomer is preferred.
  • the salts may exist in solvated, especially, hydrated, form and may hydrate on storage in a non-airtight environment.
  • the present invention provides methods for the treatment or prophylaxis of stress-related affective disorders which comprise administering to a human or animal patient an effective amount of a pamoate salt of a compound of Formula I or a pharmacologically acceptable solvate thereof.
  • the present invention provides pharmaceutical compositions comprising the pamoate salt of a compound of Formula I or a pharmacologically acceptable solvate thereof and a pharmacologically acceptable diluent or carrier.
  • the present invention provides the pamoate salts of compounds of Formula I and pharmacologically acceptable solvates thereof for use in treatments of the human or animal body by therapy or diagnosis practised on the human or animal body.
  • the present invention provides the use of pamoate salts of compounds of Formula I and pharmacologically acceptable solvates thereof in the manufacture of medicaments for the treatment or prophylaxis of stress-related affective disorders.
  • pamoate salts of compounds of Formula I include the following:
  • the preferred pamoate salts are those of compounds of Formula I in which Ri represents methoxy and R 2 represents methoxy or hydrogen.
  • the most preferred salts are 3(3,5-dimethoxyphenyl)-3-(3-dimethylaminopropyl)-4,4-dimethylpiperidine-2,6-dione pamoate and, especially, 3(3-methoxyphenyl)-3-(3-dimethylaminopropyl)-4,4- dimethylpiperidine-2,6-dione (AGN 2979) pamoate.
  • the pamoate salts of the invention can be prepared by conventional techniques for converting a free base into an acid addition salt or for converting one acid addition salt to another.
  • the pamoate salt is prepared by treating an ethanol solution of a compound of Formula I with a cooled solution of pamoic acid in ethanol; evaporation of the solvent under reduced pressure and recrystallisation of the residue from ethanol.
  • a salt of a compound of Formula I may be converted into the pamoate by neutralisation, for example with ammonium hydroxide, and subsequent treatment with pamoic acid.
  • the compounds of Formula I can be prepared by the processes disclosed in US-A-3,963,729 or US-A-5, 104,990, the disclosure of which documents are incorporated by this reference.
  • the optical isomers can be separated in conventional manner, for example the (-) isomers can be separated by crystallisation of their (+) binaphthyl phosphoric acid salts from a suitable solvent such as ethanol.
  • the pamoate salts of the compounds of Formula I have the same qualitative pharmacological activity as that previously reported for the free base and other acid addition salts, especially the hydrochloride, and is especially useful for the treatment or prophylaxis of any stress-induced affective disorder.
  • stress-induced affective disorder is used herein to include any disorder associated with elevated levels of 5-HT (5-hydroxytryptamine; serotonin) resultant from newly synthesised 5-HT.
  • the pamoate salts can be used to treat or prevent those neurological and psychological diseases and conditions in which newly synthesised 5- HT is implicated and for which antidepressant, anxiolytic and antipsychotic drugs are presently indicated.
  • Non-limiting examples of such diseases or conditions are agoraphobia; anorexia nervosa; anxiety; anxiogenisis associated with withdrawal from drugs of abuse; bulimia nervosa; chronic paroxysmal hemicrania; depression (including prevention of depressive recurrences); diminution of the immune response associated with anxiety, depression or bereavement; disorders of sleep initiation or maintenance; disorders of the sleep-awake schedule; dream anxiety attacks; Huntington's chorea; Kleine-Levin syndrome; memory disturbance; Meniere's disease, menstrual-associated sleep syndrome; migraine; motion sickness; nausea incompletely relieved by 5HT 3 antagonist administration, neurogenic pain; neuropathic pain; obsessive-compulsive disorder; panic attacks; posttraumatic stress disorder; pre-menstrual dysphoric disorder; recurrent brief depression; Restless Leg syndrome, schizophrenia; senile dementia; serotonin-irritation syndrome; sleep apnoea; sleep related cardiovascular symptoms; sleep related epileptic seizures; sleep-related
  • AGN 2979 pamoate The antidepressant action of AGN 2979 pamoate is believed to result from the inhibition of tryptophan hydroxylase activation, and the mechanism of this effect may involve blockade of K+ channels since other metabolic inhibitors, such as guanidine and sodium cyanide, which are known to open K+ channels, can activate tryptophan hydroxylase and this activation can be blocked by AGN 2979 pamoate.
  • metabolic inhibitors such as guanidine and sodium cyanide
  • the pamoate salts of the invention can be administered in any of the manners previously proposed for the hydrochloride salt. They can be administered alone or in the form of pharmaceutical preparations to the patient being treated either orally or parenterally, for example subcutaneously or intravenously.
  • the amount of pamoate salt administered will vary and can be any effective amount.
  • the quantity of pamoate salt administered may vary over a wide range to provide from about 0.1 mg/kg to about 20 mg/kg, usually about 0.5 mg/kg to about 10 mg/kg and preferably about 1 to about 5 mg/kg, of body weight of the patient per dose.
  • Unit doses of these salts can contain, for example, from about 10 mg to about 500 mg, advantageously about 25 to about 200 mg.
  • unit dosage form is used herein to mean a single or multiple dose form containing a quantity of the active ingredient in admixture with or otherwise in association with a diluent or carrier, said quantity being such that one or more predetermined units are normally required for a single therapeutic administration.
  • said predetermined unit will be one fraction, such as a 5 ml (teaspoon) quantity of a liquid or a half or quarter of a scored tablet, of the multiple dose form.
  • the pharmaceutical formulations in which form the pamoate salts of the invention will normally be utilised are prepared in a manner well known per se in the pharmaceutical art and usually comprise at least one active pamoate salt of the invention in admixture or otherwise in association with a pharmaceutically acceptable carrier or diluent therefor.
  • the active ingredient usually will be mixed with a carrier, or diluted by a diluent, or enclosed or encapsulated in a capsule, sachet, cachet, paper or other container.
  • a carrier or diluent may be solid, semi-solid or liquid material that serves as a vehicle, excipient or medium for the active ingredient. Suitable carriers or diluents are well known per se.
  • the formulations may be adapted for enteral or parenteral use and may be administered to the patient in the form of tablets, capsules, dragees, suppositories, syrups, suspensions or the like.
  • the invention is illustrated in the following non-limiting Examples.
  • the mixture was then cooled to -50°C and a solution of 6.62 g (33 mmoles) of diethyl isopropylidenemalonate in 30 ml of tetrahydrofuran was added to the reaction mixture at a rate such that the temperature did not exceed -50°C.
  • the mixture was stirred at -50°C for 30 min and the cold reaction mixture added to a stirred solution of 30 ml of aqueous hydrochloric acid (36% w/w) in 100 ml of water cooled to 10°C.
  • the mixture was extracted twice with toluene and the toluene phase is back extracted with a solution of 2 ml of hydrochloric acid (36% w/w) in 8 ml of water.
  • the aqueous acidic extract was combined with the aqueous acidic phase from above and extracted twice with 50 ml portions of methylene chloride.
  • the combined methylene chloride extracts were washed with water and the methylene chloride phase filtered and concentrated to low volume by distillation at atmospheric pressure.
  • a 100 ml portion of ethyl acetate was added and the resulting slurry cooled to 5-10°C.
  • the resulting solid was collected by filtration, washed with ethyl acetate and dried at 50°C to give 10.1 g of white powder.
  • the aqueous solution was washed with methylene chloride, the aqueous phase mixed with methylene chloride and basified with aqueous ammonium hydroxide (29% w/w) while maintaining the temperature at less than 30°C. After separation of the layers, the aqueous phase was extracted twice with methylene chloride, the combined organic phases concentrated and the residue crystallised in tert- butyl methyl ether to give 5.7 g of white powder.
  • the crude compound was suspended in 200 ml of absolute ethyl alcohol, 1 equivalent of concentrated sulphuric acid added and the mixture is heated under reflux for 30 minutes to dissolve the salt.
  • Tablets each having the following composition are prepared by conventional tabletting techniques:
  • Suppositories are formed from the following composition:
  • the compound (a) is powdered and passed through a BS No. 100 sieve (0.125 mm) and triturated with molten oil of Theobroma at 45° C. to form a smooth suspension.
  • the mixture is well stirred and poured into moulds each of nominal 1 g capacity to produce suppositories.
  • Pills each having the following composition are prepared by blending the active (a) and the corn starch (b), then adding the liquid glucose (c) with thorough kneading to form a plastic mass from which the pills are cut and formed:
  • Gelatine capsules each containing 50 mg AGN 2979 pamoate and 20 mg talc are prepared by passing AGN 2979 and talc separately through a fine mesh screen, mixing the sieved powders and filling the mixed powder into hard gelatine capsules at a net fill of 70 mg per capsule.

Abstract

Novel pamoate salts of certain 3-phenyl-3-dimethylaminoalkyl-4,4dimethylpiperidin-2,6-diones (1) and pharmacologically acceptable solvates thereof are devoid of the weight loss and hepatocyte changes in the rat which limited to marginally effective levels the permitted clinical doses of the corresponding hydrochlorides in the treatment or prophylaxis of stress-related affective disorders such as anxiety, depression, migraine and sleep apnoea. The preferred pamoate salts are 3(3,5dimethoxyphenyl)-3-(3-dimethylaminopropyl)-4,4-dimethylpiperidine-2,6-dione pamoate and, especially, 3(3-methoxyphenyl)-3-(3-dimethylaminopropyl)-4,4-dimethylpiperidine2,6-dione pamoate.

Description

NOVEL PIPERIDIN-2.6-DIONE PAMOATE SALTS AND THEIR USE FOR THF TREATMENT OF STRESS-RELATED AFFECTIVE DISORDERS.
The present invention relates to pamoate salts of certain 3-phenyl-3- dimethylaminoalkyl-4,4-dimethylpiperidin-2,6-diones and their use in the treatment of stress-related affective disorders. The term "stress-induced affective disorder" is used herein to include any disorder associated with elevated levels of 5-HT (5- hydroxytryptamine; serotonin) resultant from newly synthesised 5-HT.
3-Phenyl-3-dimethylaminoalkyl-4,4-dimethylpiperidin-2,6-diones of the following Formula I and their acid addition salts have been known since 1974 (see BE-A-808,958; corresponding to GB-A-1 ,455,687 & US-A-3,963,729):
Figure imgf000002_0001
wherein:
RT represents methoxy, ethoxy or hydroxy;
R2 represents methoxy, ethoxy, hydroxy or hydrogen; and n represents 2 or 3.
They have been reported to have a range of pharmacological activities (see US- A-3,963,729; US-A-4,461,771 ; US-A-4,738,973; US-A-4,835,151 ; US-A-4,835,151 ; US- A-4,918,084; US-A-4,994,475; US-A-5, 1177,086; GB-A-2,196,251 & GB-A-2,206,491) but were primary of interest for the treatment of stress-related affective disorders, especially anxiety and depression. They are the only compounds presently known to block selectively the activation of tryptophan hydroxylase induced by depolarisation, metabolic inhibitors, methyl xanthine, or stress. The compound of choice for clinical investigation was 3(3-methoxyphenyl)-3-(3-dimethylaminopropyl)-4,4- dimethylpiperidine-2,6-dione, which has been variously identified as AGN 2979 (which designation will be used in this application); BTG 1501 ; MDL 72415 and SC 48274. A large number of acid addition salts of AGN 2979 have been proposed but the hydrochloride has been the salt of choice because hydrochloride acid addition salts are the most commonly used acid addition salts and can be readily and inexpensively prepared and there was no reason to believe that any other salts would have any advantage over the hydrochloride. There has been no previous proposal or suggestion to use a pamoate salt of AGN 2979, or of any other base of Formula I or other 3-phenyl substituted-3-dialkylaminoalkyl-4,4-dialkylpiperidin-2,6-dione, for any purpose.
A number of papers relating to clinical trials of the hydrochloride salt of AGN 2979 have been conducted and the results published. These showed the salt to be effective in the treatment of anxiety and depression at about 4 mg/kg/day (200-400 mg/day for human patients). However, a 1-year sub-acute toxicity study of the hydrochloride (200 mg/kg/day p o. (i.e. by mouth)) in rats showed that the animals suffered an immediate and continuing weight loss (40% over the 1-year period) and, as revealed by post-mortem examination, hepatocyte changes which had not been detected by routine transaminase determinations during the year. As a result, the USA Food and Drugs Administration ("F.D.A") precluded the use of the dose levels previously used in the clinical trials. A subsequent clinical study by Cutler et al using an F.D.A. allowed dose of 1 mg b.i.d. (i.e. twice daily) (about 30 μg/kg/day) showed that the hydrochloride salt of AGN 2979 possessed only marginally effective anxiolytic properties at FDA permitted dose levels.
It has now surprisingly been found that the aforementioned problems of weight loss and hepatocyte changes can be overcome by the use of the pamoate salt instead of the hydrochloride, or other previously disclosed salt, of compounds of Formula I. These pamoate salts do not cause weight loss and the indications are that they will not cause hepatocyte changes over prolonged periods of treatment. Furthermore, it has been found that the pamoate salts of the compounds of Formula I, contrary to the known salts, are tasteless and allow the preparation of pharmaceutical compositions for the oral administration, especially in form of suspensions, syrups and the like. Thus, according to a first aspect of the present invention, there is provided the pamoate salts of 3-phenyl-3-dimethylaminoalkyl-4,4-dimethylpiperidin-2,6-diones of Formula I:
Figure imgf000004_0001
wherein:
Ri represents methoxy, ethoxy or hydroxy; R2 represents methoxy, ethoxy, hydroxy or hydrogen; and n represents 2 or 3, and pharmacologically acceptable solvates thereof.
Pamoic acid is 4,4'-methylenebis[3-hydroxy-2-naphthalenecarboxylic acid] and is also known as embonic acid.
The compounds of Formula I exist in optical isomers and accordingly the pamoate salts can be used in racemate form or as individual (+) or (-) isomers. Presently the (-) isomer is preferred. The salts may exist in solvated, especially, hydrated, form and may hydrate on storage in a non-airtight environment.
In a second aspect, the present invention provides methods for the treatment or prophylaxis of stress-related affective disorders which comprise administering to a human or animal patient an effective amount of a pamoate salt of a compound of Formula I or a pharmacologically acceptable solvate thereof.
In a third aspect, the present invention provides pharmaceutical compositions comprising the pamoate salt of a compound of Formula I or a pharmacologically acceptable solvate thereof and a pharmacologically acceptable diluent or carrier.
In a fourth aspect, the present invention provides the pamoate salts of compounds of Formula I and pharmacologically acceptable solvates thereof for use in treatments of the human or animal body by therapy or diagnosis practised on the human or animal body. In a fifth aspect, the present invention provides the use of pamoate salts of compounds of Formula I and pharmacologically acceptable solvates thereof in the manufacture of medicaments for the treatment or prophylaxis of stress-related affective disorders.
Examples of pamoate salts of compounds of Formula I include the following:
3-(3'-methoxyphenyl)-3-(2"-N,N-dimethylaminoethyl)-4,4-dimethylpiperidin-2,6- dione pamoate;
3-(3,-methoxyphenyl)-3-(3"-N,N-dimethylaminopropyl)-4,4-dimethylpiperidin-2,6- dione pamoate;
3-(3'-hydroxyphenyl)-3-(2"-N,N-dimethylaminoethyl)-4,4-dimethylpiperidin-2,6- dione pamoate;
3-(3'-hydroxyphenyl)-3-(3"-N,N-dimethylaminopropyl)-4,4-dimethylpiperidin-2,6- dione pamoate;
3-(3'-ethoxyphenyl)-3-(3"-N,N-dimethylaminopropyl)-4,4-dimethylpiperidin-2,6- dione pamoate;
3-(3',5I-dimethoxyphenyl)-3-(3"-N,N-dimethylaminopropyl)-4,4-dimethylpiperidin- 2,6-dione pamoate;
3-(3,,5'-dihydroxy)-3-(3"-N,N-dimethylaminopropyl)-4,4-dimethylpiperidin-2,6- dione pamoate; and
3-(3',5,-diethoxy)-3-(3"-N,N-dimethylaminopropyl)-4,4-dimethyl-piperidin-2,6- dione pamoate.
The preferred pamoate salts are those of compounds of Formula I in which Ri represents methoxy and R2 represents methoxy or hydrogen. The most preferred salts are 3(3,5-dimethoxyphenyl)-3-(3-dimethylaminopropyl)-4,4-dimethylpiperidine-2,6-dione pamoate and, especially, 3(3-methoxyphenyl)-3-(3-dimethylaminopropyl)-4,4- dimethylpiperidine-2,6-dione (AGN 2979) pamoate.
The pamoate salts of the invention can be prepared by conventional techniques for converting a free base into an acid addition salt or for converting one acid addition salt to another. For example, the pamoate salt is prepared by treating an ethanol solution of a compound of Formula I with a cooled solution of pamoic acid in ethanol; evaporation of the solvent under reduced pressure and recrystallisation of the residue from ethanol. Alternatively, a salt of a compound of Formula I may be converted into the pamoate by neutralisation, for example with ammonium hydroxide, and subsequent treatment with pamoic acid.
The compounds of Formula I can be prepared by the processes disclosed in US-A-3,963,729 or US-A-5, 104,990, the disclosure of which documents are incorporated by this reference. The optical isomers can be separated in conventional manner, for example the (-) isomers can be separated by crystallisation of their (+) binaphthyl phosphoric acid salts from a suitable solvent such as ethanol.
The pamoate salts of the compounds of Formula I have the same qualitative pharmacological activity as that previously reported for the free base and other acid addition salts, especially the hydrochloride, and is especially useful for the treatment or prophylaxis of any stress-induced affective disorder. As mentioned above, the term "stress-induced affective disorder" is used herein to include any disorder associated with elevated levels of 5-HT (5-hydroxytryptamine; serotonin) resultant from newly synthesised 5-HT. In particular, the pamoate salts can be used to treat or prevent those neurological and psychological diseases and conditions in which newly synthesised 5- HT is implicated and for which antidepressant, anxiolytic and antipsychotic drugs are presently indicated. Non-limiting examples of such diseases or conditions are agoraphobia; anorexia nervosa; anxiety; anxiogenisis associated with withdrawal from drugs of abuse; bulimia nervosa; chronic paroxysmal hemicrania; depression (including prevention of depressive recurrences); diminution of the immune response associated with anxiety, depression or bereavement; disorders of sleep initiation or maintenance; disorders of the sleep-awake schedule; dream anxiety attacks; Huntington's chorea; Kleine-Levin syndrome; memory disturbance; Meniere's disease, menstrual-associated sleep syndrome; migraine; motion sickness; nausea incompletely relieved by 5HT3 antagonist administration, neurogenic pain; neuropathic pain; obsessive-compulsive disorder; panic attacks; posttraumatic stress disorder; pre-menstrual dysphoric disorder; recurrent brief depression; Restless Leg syndrome, schizophrenia; senile dementia; serotonin-irritation syndrome; sleep apnoea; sleep related cardiovascular symptoms; sleep related epileptic seizures; sleep-related cluster headaches; sleep-related myoclomus syndrome; social phobia; sudden infant death syndrome; and tinnitus.
The antidepressant action of AGN 2979 pamoate is believed to result from the inhibition of tryptophan hydroxylase activation, and the mechanism of this effect may involve blockade of K+ channels since other metabolic inhibitors, such as guanidine and sodium cyanide, which are known to open K+ channels, can activate tryptophan hydroxylase and this activation can be blocked by AGN 2979 pamoate.
The pamoate salts of the invention can be administered in any of the manners previously proposed for the hydrochloride salt. They can be administered alone or in the form of pharmaceutical preparations to the patient being treated either orally or parenterally, for example subcutaneously or intravenously. The amount of pamoate salt administered will vary and can be any effective amount. Depending upon the patient and the mode of administration, the quantity of pamoate salt administered may vary over a wide range to provide from about 0.1 mg/kg to about 20 mg/kg, usually about 0.5 mg/kg to about 10 mg/kg and preferably about 1 to about 5 mg/kg, of body weight of the patient per dose. Unit doses of these salts can contain, for example, from about 10 mg to about 500 mg, advantageously about 25 to about 200 mg. usually about 50 to about 100 mg of the pamoate salt and may be administered, for example, from 1 to 4 times daily. The term "unit dosage form" is used herein to mean a single or multiple dose form containing a quantity of the active ingredient in admixture with or otherwise in association with a diluent or carrier, said quantity being such that one or more predetermined units are normally required for a single therapeutic administration. In the case of multiple dose forms such as liquids or scored tablets, said predetermined unit will be one fraction, such as a 5 ml (teaspoon) quantity of a liquid or a half or quarter of a scored tablet, of the multiple dose form.
The pharmaceutical formulations in which form the pamoate salts of the invention will normally be utilised are prepared in a manner well known per se in the pharmaceutical art and usually comprise at least one active pamoate salt of the invention in admixture or otherwise in association with a pharmaceutically acceptable carrier or diluent therefor. For making those formulations, the active ingredient usually will be mixed with a carrier, or diluted by a diluent, or enclosed or encapsulated in a capsule, sachet, cachet, paper or other container. A carrier or diluent may be solid, semi-solid or liquid material that serves as a vehicle, excipient or medium for the active ingredient. Suitable carriers or diluents are well known per se. The formulations may be adapted for enteral or parenteral use and may be administered to the patient in the form of tablets, capsules, dragees, suppositories, syrups, suspensions or the like. The invention is illustrated in the following non-limiting Examples.
Example 1 Preparation of 3(3-methoxyphenyl)-3-(3-dimethylaminopropyl)-4.4-dimethyl- piperidine-2,6-dione pamoate (AGN 2979 pamoate)
(A) Preparation of diethyl 2-[2-cyano-5-(dimethylamino)-2-(3-methoxy- phenyl)-1 ,1-dimethylpentyl] propanedioate, monohydrochloride
Figure imgf000008_0001
A nitrogen atmosphere was applied to a reaction vessel and 50 ml of dry tetrahydrofuran is added. The solvent was cooled to less than -40°C and 32 mmoles of lithium diisopropylamide in tetrahydrofuranne-heptane was added (16 ml of a 2 M solution). A solution of 6.97 g (30 mmoles) of α-[3-(dimethyIamino) propyl]-3- methoxybenzeneacetonitrile in 30 ml of tetrahydrofuran was added at less than -20°C and left at this temperature for 30 min. The mixture was then cooled to -50°C and a solution of 6.62 g (33 mmoles) of diethyl isopropylidenemalonate in 30 ml of tetrahydrofuran was added to the reaction mixture at a rate such that the temperature did not exceed -50°C. The mixture was stirred at -50°C for 30 min and the cold reaction mixture added to a stirred solution of 30 ml of aqueous hydrochloric acid (36% w/w) in 100 ml of water cooled to 10°C. The mixture was extracted twice with toluene and the toluene phase is back extracted with a solution of 2 ml of hydrochloric acid (36% w/w) in 8 ml of water. The aqueous acidic extract was combined with the aqueous acidic phase from above and extracted twice with 50 ml portions of methylene chloride. The combined methylene chloride extracts were washed with water and the methylene chloride phase filtered and concentrated to low volume by distillation at atmospheric pressure. A 100 ml portion of ethyl acetate was added and the resulting slurry cooled to 5-10°C. The resulting solid was collected by filtration, washed with ethyl acetate and dried at 50°C to give 10.1 g of white powder.
(B) Preparation of 3-(3-methoxyphenyl)-3-(3-dimethylaminopropyl]-4,4- dimethyl-piperidine-2,6-dione bisulphate salt (anhydrous)
Figure imgf000009_0001
A 250 ml round-bottomed flask was charged with 10 g of the above-prepared diethyl 2-[2-cyano-5-(dimethylamino)-2-(3-methoxyphenyl)-1 , 1 -dimethylpentyl]- propanedioate mono-hydrochloride, and a solution of 10.2 g of sulphuric acid (96% w/w) in 90 ml of water was added. The reaction mixture was refluxed for about 54 hours. When the reaction was complete (as indicated by thin layer chromatography) the solution was cooled to 25°C. The aqueous solution was washed with methylene chloride, the aqueous phase mixed with methylene chloride and basified with aqueous ammonium hydroxide (29% w/w) while maintaining the temperature at less than 30°C. After separation of the layers, the aqueous phase was extracted twice with methylene chloride, the combined organic phases concentrated and the residue crystallised in tert- butyl methyl ether to give 5.7 g of white powder. The crude compound was suspended in 200 ml of absolute ethyl alcohol, 1 equivalent of concentrated sulphuric acid added and the mixture is heated under reflux for 30 minutes to dissolve the salt. After cooling, most of the solvent was evaporated under reduced pressure and the residue was by crystallised means of a 50/50 mixture of diethylether-ethyl alcohol to give 6 g of white powder (melting point = 159°-161°C) and dried under reduced pressure. (C) Preparation of 3-(3-methoxyphenyl)-3-(3-dimethylaminopropyl]-4,4- dimethyl-piperidine-2,6-dione pamoate salt (anhydrous)
Figure imgf000010_0001
A solution of AGN-2979 bisulphate salt obtained in Step B (1 mmole, 430 mg) in 10 ml of water was mixed with methylene chloride (20 ml) and basified with aqueous ammonium hydroxide (29% w/w). After separation of the layers, the aqueous phase was extracted twice with methylene chloride. The combined organic phases were dried over anhydrous magnesium sulphate and the solvent was evaporated under reduced pressure. The residue was dissolved in ethanol (10 ml) and mixed with a hot solution of pamoic acid (embonic acid, 390 mg, 1 mmole) in hot ethanol (30 ml) and the mixture was heated to reflux. After cooling, the pamoate salt crystallised and the salt was recrystallised in hot ethanol to give a pale yellow powder (melting point = 146°-150°C.
Example 2
Tablets each having the following composition are prepared by conventional tabletting techniques:
Inαredient mg per tablet
(a) AGN 2979 pamoate 50
(b) Lactose 51.5
(c) Maize starch dried 45
(d) magnesium stearate 1.5 Example 3
Suppositories are formed from the following composition:
Ingredient mg/suppository
(a) AGN 2979 pamoate 20
(b) Oil of Theobroma (cocoa butter) 980
The compound (a) is powdered and passed through a BS No. 100 sieve (0.125 mm) and triturated with molten oil of Theobroma at 45° C. to form a smooth suspension. The mixture is well stirred and poured into moulds each of nominal 1 g capacity to produce suppositories.
Example 4
Pills each having the following composition are prepared by blending the active (a) and the corn starch (b), then adding the liquid glucose (c) with thorough kneading to form a plastic mass from which the pills are cut and formed:
Ingredient per pill
(a) AGN 2979 pamoate 50 mg
(b) Corn starch 45 mg
(c) Liquid glucose 7 cm3
Examp )le 5
Gelatine capsules each containing 50 mg AGN 2979 pamoate and 20 mg talc are prepared by passing AGN 2979 and talc separately through a fine mesh screen, mixing the sieved powders and filling the mixed powder into hard gelatine capsules at a net fill of 70 mg per capsule.

Claims

CLAIMS:
1. A pamoate salt of a 3-phenyl-3-dimethylaminoalkyl-4,4-dimethylpiperidin- 2,6-dione of Formula I:
Figure imgf000012_0001
wherein:
R^ represents methoxy, ethoxy or hydroxy; R2 represents methoxy, ethoxy, hydroxy or hydrogen; and n represents 2 or 3, or a pharmacologically acceptable solvate thereof.
2. A pamoate salt as claimed in Claim 1 , wherein Ri represents methoxy and R2 represents methoxy or hydrogen.
3. A pamoate salt as claimed in Claim 2, wherein the pamoate salt is 3(3- methoxyphenyl)-3-(3-dimethylaminopropyl)-4,4-dimethylpipehdine-2,6-dione pamoate.
4. A pamoate salt as claimed in Claim 2, wherein the pamoate salt is 3(3,5- dimethoxyphenyl)-3-(3-dimethylaminopropyl)-4,4-dimethylpiperidine-2,6-dione pamoate.
5. A pamoate salt as claimed in any one of the preceding claims, wherein the pamoate salt is in the form of its (-) isomer.
6. A pamoate salt as claimed in any one of the preceding claims, wherein the pamoate salt in the form of a hydrate.
7. A pharmaceutical composition comprising a pamoate salt of a 3-phenyl- 3-dimethylaminoalkyl-4,4-dimethylpiperidin-2,6-dione of Formula I:
Figure imgf000013_0001
wherein:
Ri represents methoxy, ethoxy or hydroxy;
R2 represents methoxy, ethoxy, hydroxy or hydrogen; and n represents 2 or 3, or a pharmacologically acceptable solvate thereof and a pharmacologically acceptable diluent or carrier.
8 A pharmaceutical composition as claimed in Claim 7 for the treatment or prophylaxis of a stress-related affective disorder.
9 A pharmaceutical composition as claimed in Claim 7 or Claim 8, wherein the 3-phenyl-3-dimethylaminoalkyl-4,4-dimethylpiperidin-2,6-dione is as defined in any one of Claims 2, 5 and 6.
10. A pharmaceutical composition as claimed in Claim 9, wherein the pamoate salt is 3(3-methoxyphenyl)-3-(3-dimethylaminopropyl)-4,4-dimethylpiperidine- 2,6-dione pamoate.
11. A pharmaceutical composition as claimed in Claim 9, wherein the pamoate salt is 3(3,5-dimethoxyphenyl)-3-(3-dimethylaminopropyl)-4,4- dimethylpiperidine-2,6-dione pamoate.
12. A pamoate salt of a 3-phenyl-3-dimethylaminoaIkyl-4,4-dimethylpiperidin- 2,6-dione of Formula I:
Figure imgf000014_0001
wherein:
Ri represents methoxy, ethoxy or hydroxy;
R2 represents methoxy, ethoxy, hydroxy or hydrogen; and n represents 2 or 3, or a pharmacologically acceptable solvate thereof for use in treatment of the human or animal body by therapy or diagnosis practised on the human or animal body.
13 A pamoate salt as claimed in Claim 12, wherein the 3-phenyl-3- dimethylaminoalkyl-4,4-dimethylpiperidin-2,6-dione is as defined in any one of Claims 2, 5 and 6.
14. A pamoate salt as claimed in Claim 13, wherein the pamoate salt is 3(3- methoxyphenyl)-3-(3-dimethyIaminopropyl)-4,4-dimethylpiperidine-2,6-dione pamoate.
15. A pamoate salt as claimed in Claim 13, wherein the pamoate salt is 3(3,5-dimethoxyphenyl)-3-(3-dimethylaminopropyl)-4,4-dimethylpiperidine-2,6-dione pamoate.
16. Use of a pamoate salt of a 3-phenyl-3-dimethylaminoalkyl-4,4-dimethyl- piperidin-2,6-dione of Formula I:
Figure imgf000015_0001
wherein:
Ri represents methoxy, ethoxy or hydroxy; R2 represents methoxy, ethoxy, hydroxy or hydrogen; and n represents 2 or 3, or a pharmacologically acceptable solvate thereof in the manufacture of a medicament for the treatment or prophylaxis of stress-related affective disorders.
17. The use as claimed in Claim 16, wherein the stress-related affective disorder is selected from agoraphobia; anorexia nervosa; anxiety; anxiogenisis associated with withdrawal from drugs of abuse; bulimia nervosa; chronic paroxysmal hemicrania; depression (including prevention of depressive recurrences); diminution of the immune response associated with anxiety, depression or bereavement; disorders of sleep initiation or maintenance; disorders of the sleep-awake schedule; dream anxiety attacks; Huntington's chorea; Kleine-Levin syndrome; memory disturbance; Meniere's disease, menstrual-associated sleep syndrome; migraine; motion sickness; nausea incompletely relieved by 5HT3 antagonist administration, neurogenic pain; neuropathic pain; obsessive-compulsive disorder; panic attacks; posttraumatic stress disorder; premenstrual dysphoric disorder; recurrent brief depression; Restless Leg syndrome, schizophrenia; senile dementia; serotonin-irritation syndrome; sleep apnoea; sleep related cardiovascular symptoms; sleep related epileptic seizures; sleep-related cluster headaches; sleep-related myoclomus syndrome; social phobia; sudden infant death syndrome; and tinnitus.
18. The use as claimed in Claim 17, wherein the medicament is for the treatment or prophylaxis of anxiety.
19. The use as claimed in Claim 17, wherein the medicament is for the treatment or prophylaxis of depression.
20. The use as claimed in Claim 17, wherein the medicament is for the treatment or prophylaxis of migraine.
21. The use as claimed in Claim 17, wherein the medicament is for the treatment or prophylaxis of sleep apnoea.
22. The use as claimed in any one of Claims 16 to 21 , wherein the 3-phenyl- 3-dimethylaminoalkyl-4,4-dimethylpiperidin-2,6-dione is as defined in any one of Claims 2, 5 and 6.
23. The use as claimed in Claim 22, wherein the pamoate salt is 3(3- methoxyphenyl)-3-(3-dimethylaminopropyl)-4,4-dimethylpiperidine-2,6-dione pamoate.
24. The use as claimed in Claim 22, wherein the pamoate salt is 3(3,5- dimethoxyphenyl)-3-(3-dimethylaminopropyl)-4,4-dimethylpiperidine-2,6-dione pamoate.
25. A method for the treatment or prophylaxis of a stress-related affective disorder which comprises administering to a human or animal patient an effective amount of a pamoate salt of a 3-phenyl-3-dimethylaminoalkyl-4,4-dimethylpiperidin-2,6- dione of Formula I:
Figure imgf000016_0001
wherein: \ represents methoxy, ethoxy or hydroxy; R2 represents methoxy, ethoxy, hydroxy or hydrogen; and n represents 2 or 3, or a pharmacologically acceptable solvate thereof.
26. A method as claimed in Claim 25, wherein the stress-related affective disorder is selected from the group consisting of agoraphobia; anorexia nervosa; anxiety; anxiogenisis associated with withdrawal from drugs of abuse; bulimia nervosa; chronic paroxysmal hemicrania; depression (including prevention of depressive recurrences); diminution of the immune response associated with anxiety, depression or bereavement; disorders of sleep initiation or maintenance; disorders of the sleep-awake schedule; dream anxiety attacks; Huntington's chorea; Kleine-Levin syndrome; memory disturbance; Meniere's disease, menstrual-associated sleep syndrome; migraine; motion sickness; nausea incompletely relieved by 5HT antagonist administration, neurogenic pain; neuropathic pain; obsessive-compulsive disorder; panic attacks; posttraumatic stress disorder; pre-menstrual dysphoric disorder; recurrent brief depression; Restless Leg syndrome, schizophrenia; senile dementia; serotonin-irritation syndrome; sleep apnoea; sleep related cardiovascular symptoms; sleep related epileptic seizures; sleep-related cluster headaches; sleep-related myoclomus syndrome; social phobia; sudden infant death syndrome; and tinnitus.
27. A method as claimed in Claim 26, wherein the stress-related affective disorder is anxiety.
28. A method as claimed in Claim 26, wherein the stress-related affective disorder is depression.
29. A method as claimed in Claim 26, wherein the stress-related affective disorder is migraine.
30. A method as claimed in Claim 26, wherein the stress-related affective disorder is sleep apnoea.
31. A method as claimed in any one of Claims 25 to 30, wherein the 3- phenyl-3-dimethylaminoalkyl-4,4-dimethylpiperidin-2,6-dione is as defined in any one of Claims 2, 5 and 6.
32. A method as claimed in Claim 31 , wherein the pamoate salt is 3(3- methoxyphenyl)-3-(3-dimethylaminopropyl)-4,4-dimethylpiperidine-2,6-dione pamoate.
33. A method as claimed in Claim 31 , wherein the pamoate salt is 3(3,5- dimethoxyphenyl)-3-(3-dimethylaminopropyl)-4,4-dimethylpiperidine-2,6-dione pamoate.
PCT/IB2003/003698 2002-08-22 2003-08-18 Piperidin-2,6-dione pamoate salts and their use for the treatment of stress-related affective disorders WO2004017970A1 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
AU2003255947A AU2003255947B2 (en) 2002-08-22 2003-08-18 Piperidin-2,6-dione pamoate salts and their use for the treatment of stress-related affective disorders
US10/524,693 US7514454B2 (en) 2002-08-22 2003-08-18 Piperidin-2,6-dione pamoate salts and their use for the treatment of stress-related affective disorders
EP03792588A EP1539160B1 (en) 2002-08-22 2003-08-18 Piperidin-2,6-dione pamoate salts and their use for the treatment of stress-related affective disorders
MXPA05001919A MXPA05001919A (en) 2002-08-22 2003-08-18 Piperidin-2,6-dione pamoate salts and their use for the treatment of stress-related affective disorders.
BR0313674-4A BR0313674A (en) 2002-08-22 2003-08-18 Compound, pharmaceutical composition, use of a compound, and method for the treatment or prophylaxis of an affective tension-related disorder
SI200330438T SI1539160T1 (en) 2002-08-22 2003-08-18 Piperidin-2,6-dione pamoate salts and their use for the treatment of stress-related affective disorders
NZ538341A NZ538341A (en) 2002-08-22 2003-08-18 Piperidin-2,6-dione pamoate salts and their use for the treatment of stress-related affective disorders
DE60306396T DE60306396T2 (en) 2002-08-22 2003-08-18 Piperidine-2,6-dion- pamoate salts and their use for the treatment of stress-related affective disorders
JP2004530467A JP2005538146A (en) 2002-08-22 2003-08-18 Novel piperidine-2,6-dione pamoate salts and methods for using them to treat and treat stress-related emotional disorders
CA002495377A CA2495377A1 (en) 2002-08-22 2003-08-18 Piperidin-2,6-dione pamoate salts and their use for the treatment of stress-related affective disorders
EA200500242A EA007900B1 (en) 2002-08-22 2003-08-18 Piperidin-2.6-dione pamoate salts and their use for the treatment of stress-related affective disorders
UAA200501443A UA80144C2 (en) 2002-08-22 2003-08-18 Piperidin-2,6-dione pamoate salts and their use for the treatment of stress-related affective disorders
IL166941A IL166941A (en) 2002-08-22 2005-02-16 Piperidin-2,6-dione pamoate salts for the treatment of stress-related affective disorders
NO20051471A NO20051471L (en) 2002-08-22 2005-03-21 Piperidine-2,6-dione pamoate salts and their use in the treatment of stress-related affective disorders
CY20061101323T CY1105541T1 (en) 2002-08-22 2006-09-15 PAMOIC SALTS OF PIPERIDINO-2,6-DIONE AND THEIR USE IN THE TREATMENT OF STRESS-RELATED EMOTIONAL DISORDERS
US12/382,511 US20090182012A1 (en) 2002-08-22 2009-03-18 Piperidin-2, 6-dione pamoate salts and their use for the treatment of affective disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0219639.2 2002-08-22
GBGB0219639.2A GB0219639D0 (en) 2002-08-22 2002-08-22 Novel piperidin-2,6-dione salts and their use for the treatment of stress-related affective disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/382,511 Continuation US20090182012A1 (en) 2002-08-22 2009-03-18 Piperidin-2, 6-dione pamoate salts and their use for the treatment of affective disorders

Publications (1)

Publication Number Publication Date
WO2004017970A1 true WO2004017970A1 (en) 2004-03-04

Family

ID=9942831

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2003/003698 WO2004017970A1 (en) 2002-08-22 2003-08-18 Piperidin-2,6-dione pamoate salts and their use for the treatment of stress-related affective disorders

Country Status (23)

Country Link
US (2) US7514454B2 (en)
EP (1) EP1539160B1 (en)
JP (1) JP2005538146A (en)
KR (1) KR20050038014A (en)
CN (1) CN1678316A (en)
AT (1) ATE330605T1 (en)
BR (1) BR0313674A (en)
CA (1) CA2495377A1 (en)
CY (1) CY1105541T1 (en)
DE (1) DE60306396T2 (en)
DK (1) DK1539160T3 (en)
EA (1) EA007900B1 (en)
ES (1) ES2268474T3 (en)
GB (1) GB0219639D0 (en)
GE (1) GEP20074051B (en)
IL (1) IL166941A (en)
MX (1) MXPA05001919A (en)
NO (1) NO20051471L (en)
NZ (1) NZ538341A (en)
PL (1) PL373416A1 (en)
PT (1) PT1539160E (en)
UA (1) UA80144C2 (en)
WO (1) WO2004017970A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016261A3 (en) * 2003-08-06 2005-06-09 Alkermes Inc Aripiprazole and haloperidol pamoate salts
WO2007031737A1 (en) * 2005-09-14 2007-03-22 Prestwick Pharmaceuticals, Inc. 4,4-dimethylpiperidine-2,6-dione derivatives for use in the treatment of hypertension
WO2013150052A1 (en) 2012-04-04 2013-10-10 Intervet International B.V. Soft chewable pharmaceutical products

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008002804A (en) * 2006-06-28 2008-04-02 Teva Pharma Crystalline forms of atorvastatin.
CN105727117A (en) * 2016-02-03 2016-07-06 瓮杰林 Medicine for treating prostatic hyperplasia and preparation method thereof
CN106831594B (en) * 2017-01-18 2018-02-02 力赛生物医药科技（厦门）有限公司 Clonidine embonate and preparation method thereof
CN115702894A (en) * 2021-08-11 2023-02-17 朱信红 A sustained-release composition for stopping emesis and its preparation method

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3963729A (en) * 1972-12-28 1976-06-15 Aspro-Nicholas Limited Pharmacologically active pyridine derivatives
WO2003020275A1 (en) * 2001-08-28 2003-03-13 Prestwick Pharmaceuticals, Inc. Novel piperidin-2,6-dione bisulphate salts and their use for the treatment of stress-related affective disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4461771A (en) * 1983-03-01 1984-07-24 Gittos Maurice W Treatment of migraine with dioxopiperidine derivatives
DE3686622T2 (en) * 1985-09-11 1993-04-01 British Tech Group USE OF DIOXOPIPERIDINE DERIVATIVES FOR THE TREATMENT OF ANXIETAS, FOR THE REDUCTION OF CHRONICALLY HORNICALLY HIGH BRAIN MIRRORS, SEROTONINS OR 5-HYDROXY INDOLESSIC ACID, AND FOR THE TREATMENT OF BACTERALIANS.
GB2196251B (en) 1986-09-08 1990-07-04 Nat Res Dev Anxiolytic compositions containing dioxopiperidine derivatives
GB8716338D0 (en) 1987-07-10 1987-08-19 Nat Res Dev Anti-anxiogenic compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3963729A (en) * 1972-12-28 1976-06-15 Aspro-Nicholas Limited Pharmacologically active pyridine derivatives
WO2003020275A1 (en) * 2001-08-28 2003-03-13 Prestwick Pharmaceuticals, Inc. Novel piperidin-2,6-dione bisulphate salts and their use for the treatment of stress-related affective disorders

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016261A3 (en) * 2003-08-06 2005-06-09 Alkermes Inc Aripiprazole and haloperidol pamoate salts
US6987111B2 (en) * 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
WO2007031737A1 (en) * 2005-09-14 2007-03-22 Prestwick Pharmaceuticals, Inc. 4,4-dimethylpiperidine-2,6-dione derivatives for use in the treatment of hypertension
GB2445888A (en) * 2005-09-14 2008-07-23 Prestwick Pharmaceuticals Inc 4,4-dimethylpiperidine-2, 6-dione derivatives for use in the treatment of hypertension
GB2445888B (en) * 2005-09-14 2010-01-06 Prestwick Pharmaceuticals Inc Treatment of hypertension
WO2013150052A1 (en) 2012-04-04 2013-10-10 Intervet International B.V. Soft chewable pharmaceutical products
US11285101B2 (en) 2012-04-04 2022-03-29 Intervet Inc. Soft chewable pharmaceutical products
US11337917B2 (en) 2012-04-04 2022-05-24 Intervet Inc. Soft chewable pharmaceutical products

Also Published As

Publication number Publication date
EA200500242A1 (en) 2005-08-25
AU2003255947A1 (en) 2004-03-11
NO20051471L (en) 2005-05-23
MXPA05001919A (en) 2005-06-03
JP2005538146A (en) 2005-12-15
US7514454B2 (en) 2009-04-07
US20090182012A1 (en) 2009-07-16
DE60306396D1 (en) 2006-08-03
US20060025443A1 (en) 2006-02-02
GB0219639D0 (en) 2002-10-02
EA007900B1 (en) 2007-02-27
DK1539160T3 (en) 2006-10-09
ATE330605T1 (en) 2006-07-15
IL166941A (en) 2010-04-15
CN1678316A (en) 2005-10-05
EP1539160B1 (en) 2006-06-21
ES2268474T3 (en) 2007-03-16
PL373416A1 (en) 2005-08-22
CA2495377A1 (en) 2004-03-04
GEP20074051B (en) 2007-02-26
UA80144C2 (en) 2007-08-27
DE60306396T2 (en) 2007-05-03
NZ538341A (en) 2006-09-29
CY1105541T1 (en) 2010-07-28
EP1539160A1 (en) 2005-06-15
KR20050038014A (en) 2005-04-25
BR0313674A (en) 2005-06-21
PT1539160E (en) 2006-10-31

Similar Documents

Publication Publication Date Title
US20090182012A1 (en) Piperidin-2, 6-dione pamoate salts and their use for the treatment of affective disorders
IE55870B1 (en) Anorexigenic trifluoromethylphenyltetrahydropyridines,a process for their preparation and pharmaceutical compositions containing them
EP1420788B1 (en) Novel piperidin-2,6-dione bisulphate salts and their use for the treatment of stress-related affective disorders
AU2002321522A1 (en) Novel piperidin-2,6-dione bisulphate salts and their use for the treatment of stress-related affective disorders
EP1137636A1 (en) Process for preparation of paroxetine maleate
AU2003255947B2 (en) Piperidin-2,6-dione pamoate salts and their use for the treatment of stress-related affective disorders
JPS59134756A (en) Dialkylaminoalkoxybenzyl alcohol derivative
US4472408A (en) Substituted trifluoromethylphenyltetrahydropyridines having an anorectic activity
HU186655B (en) Process for producing new piperidine derivatives, acid additional salts and quaternary salts and pharmaceutical compositions containing them
HU188239B (en) Process for the production of new resorcinol-derivatives and of therapeutic preparations containing them
EP0460358B1 (en) Agent for treating disorders from cerebral neuro-degeneration
EP2393778B1 (en) Optically active 3-[(phenylpiperazin-1-yl)alkyl]-3- alkyl-oxindole derivatives having CNS activity
JPH0474B2 (en)
WO2007031737A1 (en) 4,4-dimethylpiperidine-2,6-dione derivatives for use in the treatment of hypertension

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003255947

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004530467

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2495377

Country of ref document: CA

Ref document number: 2006025443

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10524693

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 166941

Country of ref document: IL

Ref document number: 1-2005-500315

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 373416

Country of ref document: PL

Ref document number: PA/a/2005/001919

Country of ref document: MX

Ref document number: 538341

Country of ref document: NZ

Ref document number: 1020057002687

Country of ref document: KR

ENP Entry into the national phase

Ref country code: GE

Ref document number: GE P

WWE Wipo information: entry into national phase

Ref document number: 2003792588

Country of ref document: EP

Ref document number: 8650

Country of ref document: GE

Ref document number: 223/CHENP/2005

Country of ref document: IN

Ref document number: 20050055

Country of ref document: UZ

Ref document number: 200500242

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 20038199149

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020057002687

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2003792588

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10524693

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 2003792588

Country of ref document: EP